Lena Moran-Adams joins Gubra today as its new Group General Counsel responsible for driving legal strategy and execution across its business.

Prior to joining Gubra, she held senior legal leadership roles at Telix Pharmaceuticals (Group General Counsel), Gilead Sciences (Head of Legal & Business Conduct, Intercontinental Region), Novartis (Global Head Legal) and Bristol Myers Squibb (Regional Senior Legal Counsel).

An experienced international in-house general counsel and leader, Lena is admitted to practice law across three continents and brings more than 25 years of experience leading legal, compliance, intellectual property and corporate governance strategy teams across multiple regions and globally. With deep international expertise and track record in the pharmaceutical and biotechnology industries, her background spans multiple practice areas, jurisdictions, and business models, ranging from start-up biotechnology companies to multinational blue-chip biopharmaceutical organizations.

Kristian Borbos, Chief Financial Officer of Gubra, commented:
“We are delighted to welcome Lena to Gubra. Her extensive international legal experience and leadership will be invaluable as we continue to grow our business and advance our proprietary pipeline. As Gubra seeks to maximize the value of its pipeline, legal expertise plays a critical role in development and commercialization and in structuring and negotiating critical business development transactions, licensing agreements, collaborations, and other strategic initiatives. Lena’s proven track record in global development and commercialization worldwide and in transactions across global healthcare organizations, combined with her strong leadership capabilities and strategic perspective, makes her an excellent addition to Gubra.”

Lena Moran-Adams commented:
“I am honored and excited to join Gubra at this pivotal stage in its journey, to help shape the company’s future for the benefit of the stakeholders and patients we all serve. The company has built a distinctive position in peptide-based drug discovery and early clinical development leveraging innovative technologies and sustainability as a competitive advantage.  I look forward to supporting its continued innovation, expansion, and advancing new medicines in key areas of unmet medical need. I am particularly attracted by Gubra’s strong scientific foundation, ethical and sustainable leadership, entrepreneurial culture, and the significant opportunities to unlock additional future long-term value through the advancement of its pipeline and strategic business development initiatives.”